Michal Mauda-Havakuk
Overview
Explore the profile of Michal Mauda-Havakuk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Golan O, Khatib M, Menes T, Freitas V, Kessner R, Neeman R, et al.
Eur J Radiol
. 2024 May;
176:111511.
PMID: 38776805
Introduction: In the last two decades there has been a paradigm shift with breast conserving surgery (BCS) being applied to larger and more extensive breast malignancies. The aim of this...
2.
Zisapel M, Seyman E, Molad J, Hallevi H, Mauda-Havakuk M, Jonas-Kimchi T, et al.
Front Med (Lausanne)
. 2024 Apr;
11:1377768.
PMID: 38651063
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) syndrome is a newly described hemato-inflammatory acquired monogenic entity that presents in adulthood. One of the main features of VEXAS syndrome is...
3.
Amitai Y, Freitas V, Golan O, Kessner R, Shalmon T, Neeman R, et al.
Eur Radiol
. 2024 Mar;
34(10):6285-6295.
PMID: 38512492
Objectives: To assess the diagnostic performance of ultrafast magnetic resonance imaging (UF-DCE MRI) in differentiating benign from malignant breast lesions. Materials And Methods: A comprehensive search was conducted until September...
4.
Mauda-Havakuk M, Hawken N, Owen J, Mikhail A, Starost M, Karim B, et al.
J Hepatocell Carcinoma
. 2023 Nov;
10:1973-1990.
PMID: 37954494
Objectives: Local and systemic immune responses evoked by locoregional therapies such as cryoablation are incompletely understood. The aim of this study was to characterize cryoablation-related immune response and the capacity...
5.
Mikhail A, Morhard R, Mauda-Havakuk M, Kassin M, Arrichiello A, Wood B
Adv Drug Deliv Rev
. 2023 Sep;
202:115083.
PMID: 37673217
Although systemic immunotherapy has achieved durable responses and improved survival for certain patients and cancer types, low response rates and immune system-related systemic toxicities limit its overall impact. Intratumoral (intralesional)...
6.
Esparza-Trujillo J, Pritchard W, Mauda-Havakuk M, Starost M, Wakim P, Zeng J, et al.
Comp Med
. 2023 Mar;
73(2):127-133.
PMID: 36914240
We characterized cryoablation as a mode of clinical intervention in adult woodchucks with hepatocellular carcinoma (HCC). Woodchucks ( = 4) were infected with woodchuck hepatitis virus at birth and developed...
7.
Negussie A, Mikhail A, Owen J, Hong N, Carlson C, Tang Y, et al.
Sci Rep
. 2023 Mar;
13(1):3559.
PMID: 36864180
No abstract available.
8.
Negussie A, Mikhail A, Owen J, Hong N, Carlson C, Tang Y, et al.
Sci Rep
. 2022 Dec;
12(1):21886.
PMID: 36535979
Hepatocellular carcinoma (HCC) is an aggressive liver cancer with limited effective treatment options. In this study, we selected TLR agonists imiquimod (IMQ), gardiquimod (GARD), GS-9620 and DSR 6434, and a...
9.
Mauda-Havakuk M, Hawken N, Owen J, Mikhail A, Saxena A, Karim B, et al.
Sci Rep
. 2022 Oct;
12(1):18229.
PMID: 36309550
The immune response to radiofrequency ablation (RFA) and cryoablation (CRA) was characterized and compared in a colon cancer mouse model. All studies were conducted under a research protocol approved by...
10.
Mikhail A, Pritchard W, Negussie A, Inkiyad G, Long D, Mauda-Havakuk M, et al.
Invest Radiol
. 2022 Mar;
57(8):495-501.
PMID: 35239613
Objectives: The aims of this study were to develop a model to estimate drug dose delivered to tumors after transarterial chemoembolization (TACE) with radiopaque drug-eluting beads (DEBs) based on DEB...